Article Figures & Data
Figures
- Figure 1
- Flow chart of database search and studies selection.
- Figure 2
- Mortality in patients using prophylactic anticoagulants versus therapeutic anticoagulants.
- Figure 3
- Mortality in patients not using any anticoagulants versus prophylactic anticoagulants.
- Figure 4
- Funnel plot of standard error by log odds ration. Studies with anticoagulation versus no anticoagulation.
- Figure 5
- Funnel plot of standard error by log odds ration. Mortality in patients using prophylactic anticoagulants versus therapeutic anticoagulants.
Tables
Inclusion criteria Exclusion criteria Randomized controlled trials, controlled (non-randomized) clinical trials or cluster trials, prospective and retrospective comparative cohort studies, and case-control or nested case-control studies. Cross-sectional studies, case series, and case reports. Studies involving the general adult human population who are 18 years of age or older. Studies that involve COVID-19 patients who are receiving anticoagulation as an intervention during their hospital stay to affect mortality. Studies with a population of non-COVID-19 hospitalizations. Studies in the English language. Study name, author, year and country Total number of patients Males Mean age No anticoagulation group Prophylactic anticoagulation 1. D-dimer-driven anticoagulation reduces mortality in intubated COVID-19 patients: A cohort study with a propensity matched analysis (Tassiopoulos et al, 2021, USA)29 195 141 59.5 0 104 2. Preliminary experience with low molecular weight heparin strategy in COVID-19 patients (Paolisso et al, 2020, USA)30 450 68 74 361 3. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) (Lemos et al, 2020, Iran)31 562 325 62 0 220 4. Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study (Helms 2020, France)32 179 130 62 0 108 5. Optimizing management to reduce the mortality of COVID-19: Experience from a designated hospital for severely and critically Ill patients in China (Zhu 2021, China)33 2212 1047 34 0 220 6. Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risk and benefits (Yu et al, 2021, USA)34 235 60 60 NA 115 7. Beneficial effects of intermediate dosage of anticoagulation treatment on the prognosis of hospitalized covid 19 patients. (Poulakou, 2021, Greece)35 12 1 2 1 26 8. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events ECMO or mortality among patients with covid-19 admitted to the intensive care unit (Sadeghipour et al, 2021, Iran)36 222 117 119 NA 220 9. Intermediate dose anticoagulation aspirin and in-hospital mortality in covid 19: A propensity score-matched analysis (Meizlish et al, 2021, USA)37 531 104 145 46 536 10. Therapeutic anticoagulation with Heparin in critically ill patients with covid-19 (Goliggher et al, 2021, United Kingdom, USA, Canada, Brazil)38 200 567 200 NA 70 11. Clinical presentation, course, and risk factors associated with mortality in a severe outbreak of covid-19 in Rhode Island, USA, April-June 2020 (Atalla et al, 2020, USA)39 NA 18 NA 7 3627 12. Early initiation of prophylactic anticoagulation for prevention of Coronavisrus disease 2019 mortality in patients admitted to the hospital in the United States: cochort study (Rentsch et al, 2021, USA)40 NA 678 NA 96 1395 USA: United States of America, Yrs: years, NA: not available Study name, author, year and country Therapeutic anticoagulation Mortality in prophylactic anticoagulation group Mortality in therapeutic anticoagulation group Mortality in no anticoagulation group 1. D-dimer-driven anticoagulation reduces mortality in intubated COVID-19 patients: A cohort study with a propensity matched analysis (Tassiopoulos et al, 2021, USA)29 91 27.4 58.6 NA 2. Preliminary experience with low molecular weight heparin strategy in COVID-19 patients (Paolisso et al, 2020, USA)30 89 67 4 NA 3. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) (Lemos et al, 2020, Iran)31 222 117 119 NA 4. Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study (Helms 2020, France)32 71 20 11 NA 5. Optimizing management to reduce the mortality of COVID-19: Experience from a designated hospital for severely and critically Ill patients in China (Zhu 2021, China)33 64.6 3.7 6. Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risk and benefits (Yu et al, 2021, USA)34 235 60 60 NA 7. Beneficial effects of intermediate dosage of anticoagulation treatment on the prognosis of hospitalized covid 19 patients. (Poulakou, 2021, Greece)35 12 1 2 1 8. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events ECMO or mortality among patients with covid-19 admitted to the intensive care unit (Sadeghipour et al, 2021, Iran)36 222 117 119 NA 9. Intermediate dose anticoagulation aspirin and in-hospital mortality in covid 19: A propensity score-matched analysis (Meizlish et al, 2021, USA)37 531 104 145 46 10. Therapeutic anticoagulation with Heparin in critically ill patients with covid-19 (Goliggher et al, 2021, United Kingdom, USA, Canada, Brazil)38 200 567 200 NA 11. Clinical presentation, course, and risk factors associated with mortality in a severe outbreak of covid-19 in Rhode Island, USA, April-June 2020 (Atalla et al, 2020, USA)39 NA 18 NA 7 12. Early initiation of prophylactic anticoagulation for prevention of Coronavisrus disease 2019 mortality in patients admitted to the hospital in the United States: cochort study (Rentsch et al, 2021, USA)40 NA 678 NA 96 USA: United States of America, vs: versus, REMAP-CAP: Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia, NA: not available
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.